Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseAetna Ribavirin (Virazole) Coverage Update | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0155

    Ribavirin (Virazole) Inhalation

    Customize your policy alerts

    Sign up for Aetna Policy 0155 alerts

    Get alerted when Policy 0155 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for inhaled ribavirin (Virazole), including medically necessary indications (selected viral infections) and investigational/not-covered indications; intended for clinical and billing staff assessing medical necessity and coding.

    Policy Summary
    PayerAetna
    PolicyRibavirin (Virazole) Inhalation
    Policy CodePolicy 0155
    Change TypeNo material change
    Effective Date03/31/1997
    Last ReviewMar 31, 2023
    Next Review Date02/09/2024
    Key ActionWhen requesting coverage for inhaled ribavirin, document the specific diagnosis and the patient's immunosuppressed or high-risk status and obtain prior authorization to confirm the indication meets medical necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MultipleReferences supporting evidence summary
    Phase I-IIIStudy phases referenced
    1997Policy effective date

    Medically Necessary and Not Covered Indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medically Necessary

    Aetna considers inhaled ribavirin (Virazole) medically necessary for treatment of the following diagnoses/conditions:

    ANY of the following

    • Respiratory syncytial virus (RSV) infection in immunosuppressed and high risk children and adults
    • Viral hemorrhagic fever (Crimean-Congo, Ebola, Lassa, and Marburg)
    • Rift valley fever and Hantaan (a hanta virus)

    Experimental and Investigational (Not Covered)

    Ribavirin inhalation is considered experimental and investigational for all other indications because effectiveness has not been established. Examples include (not all-inclusive):

    ANY of the following

    • Acute myeloid leukemia
    • Coronavirus disease 2019 (COVID-19)
    • Foot-and-mouth disease
    • Glioblastomas
    • Hepatitis E infection
    • Multiple sclerosis
    • Oral cancer
    • Parainfluenza viral infections in immunocompromised individuals
    • Thyroid cancer
    Dosing / Thresholds
    Recommended inhalation dosing (Virazole)20 mg/mL solution in SPAG-2 reservoir; continuous aerosol administration 12-18 hours/day for 3-7 days; average aerosol concentration ~190 mcg/L for 12-hour delivery

    Relevant Billing and Diagnosis Codes

    Related CPT code mentionedCPT
    90378Respiratory syncytial virus, monoclonal antibody, recombinant for intramuscular use, 50 mg each

    Documentation and Authorization Requirements

    Documentation Required

    Document indication and high-risk/immunosuppressed status

    When requesting coverage for inhaled ribavirin, document the specific diagnosis (eg, RSV, specified viral hemorrhagic fever, Rift Valley fever, Hantaan) and patient's immunosuppressed or high-risk status that meets the medical necessity criteria.

    • J21.0
    • B33.24
    • A98.0
    • A92.0-A92.9
    • B33.4
    • B97.4
    Prior Authorization

    Prior authorization implied for inhaled ribavirin

    Coverage is conditional on selection criteria being met; providers should obtain prior authorization when billing for inhaled ribavirin to ensure the indication aligns with policy-stated medically necessary conditions.

    Clinical and Evidence Context

    Virazole (ribavirin for inhalation solution, USP) is the inhaled formulation of ribavirin and is FDA‑approved for treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV) (Virazole product information). The policy focuses specifically on the inhaled (Virazole) formulation delivered via the SPAG‑2 aerosol generator and references the manufacturer dosing recommendation of a 20 mg/mL solution in the SPAG‑2 reservoir with continuous aerosol administration for 12–18 hours/day for 3–7 days, yielding an average aerosol concentration of about 190 mcg/L for a 12‑hour delivery period (Virazole prescribing information and CPB dosing note).

    Beyond the approved RSV indication, the policy reviews evidence for use of ribavirin across multiple other infectious and non‑infectious conditions. The literature cited in the CPB describes variable and often limited evidence supporting off‑label uses, including oral and systemic ribavirin data for hepatitis E (HEV) (case reports, small series and retrospective studies showing viral clearance in some solid‑organ transplant patients but with dose‑limiting anemia), and older studies or case series for hepatitis C (HCV) and other viral infections (background HEV and HCV reports).

    For respiratory and emerging viral indications the CPB summarizes mixed and inconclusive data: inhaled or systemic ribavirin has been used for RSV and parainfluenza in immunocompromised patients with limited observational evidence (case series and small, uncontrolled reports) suggesting possible benefit if given early but without high‑quality randomized data; inhaled ribavirin aerosol formulations have been explored for coronaviruses including COVID‑19 in early‑phase and small clinical trials, yielding preliminary pharmacokinetic/safety data and limited efficacy signals that require further controlled study (phase I/II trials and open‑label reports).

    Ribavirin has also been studied or reported in a range of other contexts (viral hemorrhagic fevers such as Lassa, Crimean‑Congo, Ebola/Marburg; Rift Valley and hantaan viruses; oncology indications including glioblastoma, thyroid and oral cancers; and veterinary/experimental settings such as foot‑and‑mouth disease). The CPB notes that evidence quality varies widely across these areas — from guideline recommendations and systematic reviews raising questions about benefit in some hemorrhagic fevers to in‑vitro and preclinical anti‑tumor activity — and concludes that effectiveness for most of these non‑RSV indications has not been established.

    Consistent with the variable evidence base, the policy designates inhaled ribavirin as medically necessary for a limited set of serious viral infections when selection criteria are met (RSV in high‑risk or immunosuppressed patients; specified viral hemorrhagic fevers; Rift Valley and Hantaan infections) and labels other uses as experimental and investigational (not covered) because effectiveness has not been established (examples listed include acute myeloid leukemia, COVID‑19, hepatitis E, parainfluenza in some settings, glioblastoma, thyroid and oral cancers).

    At-a-Glance Evidence Metrics
    References supporting evidence summaryMultiple clinical trials and reviews cited
    Study phases referencedPhase I-III studies discussed
    Policy effective dateEffective since 1997

    Defined Terms

    VirazoleRibavirin for inhalation solution, USP (inhaled powder/solution formulation used with SPAG-2 aerosol generator).
    SPAG-2Small Particle Aerosol Generator-2 unit used to deliver inhaled ribavirin solution.

    See Also

    Related Aetna Policies
    Synagis (Palivizumab)Policy 0318 — read_with
    Policy Summary
    PayerAetna
    PolicyRibavirin (Virazole) Inhalation
    Policy CodePolicy 0155
    Change TypeNo material change
    Effective Date03/31/1997
    Last ReviewMar 31, 2023
    Next Review Date02/09/2024
    Key ActionWhen requesting coverage for inhaled ribavirin, document the specific diagnosis and the patient's immunosuppressed or high-risk status and obtain prior authorization to confirm the indication meets medical necessity criteria.
    SourceLink
    On This Page
    Medically Necessary and Not Covered IndicationsRelevant Billing and Diagnosis CodesDocumentation and Authorization RequirementsClinical and Evidence ContextDefined TermsSee Also